Evidence map›Paper›PMID 34521349›Full record

ArticleBMC neuroscience2021

Ceftriaxone therapy attenuates brain trauma in rats by affecting glutamate transporters and neuroinflammation and not by its antibacterial effects.

Sher-Wei Lim, Hui-Chen Su, Tee-Tau Eric Nyam, Chung-Ching Chio, Jinn-Rung Kuo, Che-Chuan Wang

Open access · goldAbstract read
In one paragraph

Article in BMC neuroscience, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.1field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 20 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Adenosine ANeuropharmacology · 2025
    Article
  5. Article
  6. Article
  7. Article
  8. Ceftriaxone attenuates Poly I:C-induced neuroinflammationFrontiers in cellular neuroscience · 2025
    Article
  9. Review
  10. Review
  11. Review
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Sher-Wei Lim *Department of Neurosurgery, Chi-Mei Medical Center, Chiali, Tainan, Taiwan.
Hui-Chen Su *Departments of Pharmacy, Chi-Mei Medical Center, Tainan, Taiwan.
Tee-Tau Eric NyamDepartments of Neurosurgery, Chi-Mei Medical Center, 901 Chung Hwa Road, Yung Kang City, Tainan, Taiwan.
Chung-Ching ChioDepartments of Neurosurgery, Chi-Mei Medical Center, 901 Chung Hwa Road, Yung Kang City, Tainan, Taiwan.
Jinn-Rung KuoDepartments of Neurosurgery, Chi-Mei Medical Center, 901 Chung Hwa Road, Yung Kang City, Tainan, Taiwan.
Che-Chuan WangDepartments of Neurosurgery, Chi-Mei Medical Center, 901 Chung Hwa Road, Yung Kang City, Tainan, Taiwan. wangchechuan@gmail.com.
Chi Mei Medical Center · TWMin-Hwei College of Health Care Management · TW

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCeftriaxone is a β-lactam antibiotic used to treat central nervous system infections. Whether the neuroprotective effects of ceftriaxone after TBI are mediated by attenuating neuroinflammation but not its antibacterial actions is not well established.

methodsAnesthetized male Sprague-Dawley rats were divided into sham-operated, TBI + vehicle, and TBI + ceftriaxone groups. Ceftriaxone was intraperitoneally injected at 0, 24, and 48 h with 50 or 250 mg/kg/day after TBI. During the first 120 min after TBI, we continuously measured heart rate, arterial pressure, intracranial pressure (ICP), and cerebral perfusion pressure. The infarct volume was measured by TTC staining. Motor function was measured using the inclined plane. Glutamate transporter 1 (GLT-1), neuronal apoptosis and TNF-α expression in the perilesioned cortex were investigated using an immunofluorescence assay. Bacterial evaluation was performed by Brown and Brenn's Gram staining. These parameters above were measured at 72 h after TBI.

resultsCompared with the TBI + vehicle group, the TBI + ceftriaxone 250 mg/kg group showed significantly lower ICP, improved motor dysfunction, reduced body weight loss, decreased infarct volume and neuronal apoptosis, decreased TBI-induced microglial activation and TNF-α expression in microglia, and increased GLT-1 expression in neurons and microglia. However, the grades of histopathological changes of antibacterial effects are zero.

conclusionsThe intraperitoneal injection of ceftriaxone with 250 mg/kg/day for three days may attenuate TBI by increasing GLT-1 expression and reducing neuroinflammation and neuronal apoptosis, thereby resulting in an improvement in functional outcomes, and this neuroprotective effect is not related to its antibacterial effects.

Indexed as

Anti-Bacterial AgentsAnimalsAnti-Inflammatory AgentsBrain Injuries, TraumaticCeftriaxoneDose-Response Relationship, DrugExcitatory Amino Acid Transporter 2MaleNeuroinflammatory DiseasesNeuroprotective AgentsRatsRats, Sprague-DawleyAnti-Bacterial AgentsAnti-Inflammatory AgentsCeftriaxoneExcitatory Amino Acid Transporter 2Neuroprotective AgentsSlc1a2 protein, ratApoptosisCeftriaxoneGlutamate receptor NeuroinflammationGlutamate transporterTraumatic brain injury

Identifiers

PMID34521349
PMCPMC8439027
OpenAlexW3200041221

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.